Showing results (1-10 of 93) with videos related to
Sort By:
Pageof 10
Journal of Managed Care & Specialty Pharmacy|August 23, 2023
Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitorsDavid Stenehjem, Solomon J Lubinga, Aozhou Wu, et al.Future Oncology (London, England)|January 19, 2024
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancerKeith A Betts, Sophie Gao, Saurabh Ray, et al.Clinical Therapeutics|September 25, 2023
Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To HarmRyan Sugarman, Keith A Betts, Xiaoyu Nie, et al.Rheumatology International|June 18, 2017
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspectiveM Elaine Husni, Keith A Betts, Jenny Griffith, et al.Clinical Therapeutics|July 22, 2017
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and GermanyNanxin Li, Keith A Betts, Andrew J Messali, et al.Journal of Attention Disorders|July 12, 2018
Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United StatesZhou Zhou, Keith A Betts, Iryna Bocharova, et al.Rheumatology and Therapy|May 6, 2019
Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic ArthritisYan Song, Keith A Betts, Yichen Lu, et al.Journal of Medical Economics|July 12, 2019
Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in JapanFumiaki Ueno, Michio Doi, Yumi Kawai, et al.The Journal of Dermatological Treatment|June 14, 2017
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in JapanShinichi Imafuku, Ataru Nakano, Hidetoshi Dakeshita, et al.Journal of the American Academy of Dermatology|August 2, 2016
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasisApril W Armstrong, Keith A Betts, Murali Sundaram, et al.Pageof 10